Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data ...
Preclinical data demonstrates IMR-687 reduces white cell pathologies associated with the disease Phase 1 clinical study demonstrates once-daily, oral dosing IMR-687 is safe and well-tolerated at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback